Zafrira Avnur
Chief Scientific Officer @ Quark Venture
Cupertino, United States
Zafrira Avnur is a Series A investor at Quark Venture in Cupertino focused on Life Science and Therapeutics. Zafrira Avnur - Chief Scientific Officer @ Quark Venture
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Zafrira Avnur invests in
Stages Zafrira Avnur invests in
Countries Zafrira Avnur invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Life Science 2 (67%)
- Therapeutics 2 (67%)
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Information Technology 1 (33%)
Stage
- Series A 2 (67%)
- Series D 1 (33%)
Country
- United States 2 (67%)
- Spain 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CalciMedica
|
CalciMedica was founded in December 2006 by Gonul Velicelebi, Ph.D., Kenneth Stauderman, Ph.D. and Jack Roos, Ph.D., all previously with TorreyPines Therapeutics, where they discovered the role of STIM1 in the Icrac pathway in 2003. Other co-founders, all from the CBR Institute, include Anjana Rao, Ph.D., Patrick Hogan, Ph.D. and Stefan Feske, M.D,who identified Orai1 as the CRAC channel subunit in 2006. | $21M / Series D / Mar 11, 2021 | |
EnClear Therapies
|
EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will targetimproving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | $10M / Series A / Feb 19, 2020 | |
ABAC Therapeutics
|
ABAC Therapeutics is aimed at seeking first-in-class drugs for precision treatment of MDR Gram-negative infections. While potent pathogen-specific antibacterial activity is essential, we believe that it is necessary to incorporate early other pharmaceutical properties, such as suitable pharmacokinetics and toxicological characteristics, to maximizethe chance of success in clinical development. | $17.6M / Series A / Feb 15, 2018 |
Co-Investors
About Quark Venture
Established in 2015, Quark Venture Inc. is a venture capital investment firm, headquartered in Vancouver, Canada, and is focused on equity financing of innovative biotechnology and health sciences companies with breakthrough technology platforms and projects.
Quark Venture Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Karimah Es Sabar
Chief Executive Officer & Partner
|
|||
Neena Kadaba
Director, Science
|
|||
|
Zafrira Avnur
Chief Scientific Officer
|
|||
|
Jesson Chen
Co-Founder, Chairman & Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Zafrira Avnur invest in?
Zafrira Avnur invests primarily in Life Science, Therapeutics and Biotechnology startups, most often at Series A and Series D stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Zafrira Avnur?
Public channels for Zafrira Avnur include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Zafrira Avnur last invest?
The most recent investment recorded for Zafrira Avnur closed in Mar 2021. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
